Patents Assigned to Secretary, DHHS
-
Patent number: 11555013Abstract: Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (DA), serotonin (5-HT), and/or norepinephrine (NE) reuptake via their respective transporters, DAT, SERT and NET. Also disclosed are methods for eliciting a wake-promoting or cognitive or attention enhancing effect and for treating substance use disorders, attention deficit (hyperactivity) disorder, depressive disorders, bipolar disorder or other neuropsychiatric disorders sleep disorders or cognitive impairment using the compounds.Type: GrantFiled: December 31, 2020Date of Patent: January 17, 2023Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DHHSInventors: Amy Hauck Newman, Oluyomi M. Okunola-Bakare, Jianjing Cao
-
Patent number: 11547708Abstract: A composition for preserving viability of cells, tissues, or organs at a low temperature is provided. The composition includes a mitochondrial uncoupling agent, at least one protease inhibitor, and a reducing agent. Methods to protect cells, tissues, or organs from exposure to cold and other metabolic stress are also provided.Type: GrantFiled: August 20, 2018Date of Patent: January 10, 2023Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DHHSInventors: Jingxing Ou, Wei Li, Kiyoharu Josh Miyagishima
-
Patent number: 11421219Abstract: Expression vectors, viral particles and therapeutic methods of using such constructs to improve the visual function of a patient suffering from diseases of the eye, resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye, particularly Leber Congenital Amaurosis (LCA) and CEP290-related LCA.Type: GrantFiled: May 28, 2019Date of Patent: August 23, 2022Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DHHSInventors: Zhijian Wu, Anand Swaroop, Suddhasil Mookherjee, Suja Hiriyanna
-
Patent number: 11390651Abstract: Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.Type: GrantFiled: August 31, 2020Date of Patent: July 19, 2022Assignees: The USA, Secretary, DHHS, Codagenix, Inc.Inventors: Cyril Lenouen, Ursula J. Buchholz, Peter L. Collins, Steffen Mueller
-
Patent number: 11382990Abstract: Described herein are X-ray imageable polymers such as polymeric particles comprising bismuth as a radiopacifying agent, methods of making the polymers, and methods of using the polymers. The imageable particles may comprise a covalently bound compound which chelates the bismuth, for example, through a combination of nitrogen and oxygen atoms.Type: GrantFiled: October 31, 2017Date of Patent: July 12, 2022Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DHHSInventors: Ayele H. Negussie, Bradford Johns Wood
-
Patent number: 10130700Abstract: This disclosure provides compositions that include a mixture of viral like particles (VLPs), expressing different individual influenza hemagglutinin (HA) proteins that elicit broadly reactive immune responses to a wide variety of influenza viruses. For example, the composition can include at least two different influenza VLPs, a first VLP comprising a first HA polypeptide and a second VLP comprising a second influenza HA polypeptide, wherein the first and the second HA polypeptide are different subtypes and/or are from different influenza viruses, and a pharmaceutically acceptable carrier and/or an adjuvant. Methods of using the disclosed polymeric influenza VLP compositions to stimulate an immune response against influenza viruses, for example as a pre-pandemic or a seasonal vaccine, are provided.Type: GrantFiled: May 8, 2015Date of Patent: November 20, 2018Assignee: The United States of America, as represented by the Secretary, DHHSInventor: Jeffery K. Taubenberger
-
Patent number: 9464324Abstract: Methods are disclosed for determining the prognosis of a subject with an adenocarcinoma in an organ, such as the lung. The methods can include quantitating expression of a plurality of cytokines of interest, such as IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-? and TNF-a in the adenocarcinoma and in non-cancerous tissue in the organ. Altered expression of IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-? and TNF-a in the adenocarcinoma as compared to a control and in non-cancerous tissue in the organ as compared to a control determines the prognosis for the subject. Methods for determining if a therapeutic agent is effective as an anti-cancer agent are also disclosed.Type: GrantFiled: July 16, 2007Date of Patent: October 11, 2016Assignee: The United States of America as represented by the Secretary, DHHSInventors: Curtis C. Harris, Masahiro Seike, Xin Wei Wang
-
Patent number: 9249217Abstract: We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific.Type: GrantFiled: November 15, 2011Date of Patent: February 2, 2016Assignees: Secretary, DHHS, Duke UniversityInventors: Darell D. Bigner, Chien-Tsun Kuan, John H. Sampson, Mingqing Cai, Bryan D. Choi, Ira H. Pastan
-
Publication number: 20150203547Abstract: The inventors have identified Pfs47, a gene from the malaria parasite P. falciparum, as a key factor for survival of these parasites in the mosquito Anopheles gambiae. A. gambiae is a major natural vector of human malaria in Africa. The Pfs47 protein may allow the parasite to survive in the mosquito by manipulating the mosquito's immune system. The inventors propose the use of P47 proteins, including Pfs47 and Pvs47 as a target of vaccines or pharmaceutical agents that will block or reduce P. falciparum or P. vivax infection in A. gambiae or other anopheline mosquitoes and thus prevent further transmission of the parasites in humans.Type: ApplicationFiled: August 16, 2013Publication date: July 23, 2015Applicant: The United States of America, as represented by the Secretary, DHHSInventors: Carolina Veronica Barillas-Mury, Alvaro Molina-Cruz
-
Patent number: 8041412Abstract: Systems and methods for obtaining position sensor space data regarding an endovascular prosthesis within an anatomical region of a patient include at least one position indicating element which is movable within an endovascular prosthesis is tracked by a tracking system. A guidance portion of the endovascular prosthesis constrains movement of position indicating elements within the endovascular prosthesis.Type: GrantFiled: June 11, 2007Date of Patent: October 18, 2011Assignees: Koninklijke Philips Electronics N.V., The United States of America, as represented by the Secretary DHHSInventors: Neil David Glossop, Bradford Johns Wood
-
Publication number: 20090291923Abstract: The invention provides novel trioxane dimers having formulae III, IV or V: methods for their preparation, pharmaceutical compositions containing these compounds, and methods for treating cancer and/or malaria using these compounds and compositions.Type: ApplicationFiled: November 17, 2006Publication date: November 26, 2009Applicants: Johns Hopkins Universoty, The Government of the United States of America as Represented by the Secretary of the DHHS NIH, OffiInventors: Gary H. Posner, Ikhyeon Paik, Kristina Borstnik, Wonsuk Chang, Sandra Sinishtaj, William Malo, John Gaetano D'Angelo, Lauren Elaine Woodard, Alvin Solomon Kalinda, Aimee R. Usera, Lindsey Catherine Hess, Andrew Scott Rosenthal, Seongho Oh, Astrid C. Baege
-
Publication number: 20090289630Abstract: An apparatus for imaging includes: a radio frequency (RF) coil array having a first RF coil and at least one additional RF coil, where the RF coil array is adapted to generate an image signal; a preamplifier having an input impedance, where the preamplifier is adapted to receive the image signal from the first RF coil; and a transformer to couple the first RF coil to the preamplifier, where impedance of the transformer is adapted to match the input impedance of the preamplifier.Type: ApplicationFiled: April 6, 2007Publication date: November 26, 2009Applicant: The Government of the United States of America, represented by The Secretary, DHHSInventors: George Nascimento, Afonso C. Silva
-
Publication number: 20090208409Abstract: A detection agent, including a polymerized liposome, a lectin, and an imaging agent, can be administered to an animal for the detection of polyps in the lower gastrointestinal tract.Type: ApplicationFiled: February 13, 2009Publication date: August 20, 2009Applicant: The Government of the United States of America, as represented by the Secretary, DHHSInventors: Ronald M. Summers, Jianwu Xie, Celeste A. Roney
-
Patent number: 7547712Abstract: The present invention relates methods for reducing the adverse effects of nicotine. This application describes the use of nicotine carrier conjugates in decreasing the toxic effects of nicotine on a fetus.Type: GrantFiled: February 26, 2007Date of Patent: June 16, 2009Assignees: Nabi Biopharmaceuticals, United States of America as Represented by the Secretary, DHHS Office of Technology Transfer, National Institutes of HealthInventors: Sofiane Ennifar, Scott Winston, James Terrill, Steve Fuller
-
Publication number: 20090142332Abstract: The present invention relates to methods of determining colorectal cancer status in a subject. The invention further relates to kits for determining colorectal cancer status in a subject. The invention further related to methods of identifying biomarker for determining colorectal cancer status in a subject.Type: ApplicationFiled: March 22, 2006Publication date: June 4, 2009Applicant: Government of the US, as represented by the Secretary, DHHSInventors: Thomas Ried, Jens Habermann
-
Publication number: 20090118608Abstract: A magnetic resonance imaging scanner acquires diffusion-weighted imaging data. A reconstruction engine reconstructs the acquired diffusion-weighted imaging data into diffusion-weighted image representations. A diffusion tensor engine constructs a diffusion tensor map of an area of an interest of a subject. An eigenvalue/eigenvector ordering engine obtains and orders eigenvectors and eigenvalues at each voxel. A covariance matrix determining engine constructs a covariance matrix of a major eigenvector of each voxel. A first normalized measure determining engine computes a first normalized measure. A second normalized measure determining engine computes a second normalized measure. A rendering engine generates a human-viewable display of an image representation.Type: ApplicationFiled: November 3, 2008Publication date: May 7, 2009Applicant: The Government of the United States of America, represented by The Secretary, DHHSInventor: Cheng Guan Koay
-
Publication number: 20060165652Abstract: A method of promoting the regression of a cancer in a mammal comprising: (i) administering to the mammal nonmyeloablative lymphodepleting chemotherapy, and (ii) subsequently administering: (a) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, and rapidly expanded in vitro only once, and, either concomitantly with the autologous T-cells or subsequently to the autologous T-cells, by the same route or a different route, a T-cell growth factor that promotes the growth and activation of the autologous T-cells, or (b) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, modified to express a T-cell growth factor that promotes the growth and activation of the autologous T-cells, and rapidly expanded in vitro only once, whereupon the regression of the cancer in the mammal is promoted.Type: ApplicationFiled: September 5, 2003Publication date: July 27, 2006Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRE- SENTED BY THE SECRETARY DHHSInventors: Mark Dudley, Steven Rosenberg, John Wunderlich
-
Patent number: 5462852Abstract: An antigen capture method, and an antigen capture assay diagnostic kit, for detecting the presence or concentration of HIV in a biological sample without interference from antigen-antibody immune complexes is provided. The lysate of a biological sample obtained from an animal is contacted with a detectable amount of an antibody specifically reactive with the nucleocapsid p7 antigen or an immunoreactive fragment of the p7 antigen for a time and under conditions sufficient for p7 antigen contained in the lysate to form a p7-antibody complex. The presence or concentration of this p7-antibody complex is determined to detect or quantitate the presence of HIV in the biological sample. Uses of this assay and method include detecting the presence of HIV infection in an infant born to an HIV-infected mother, monitoring the progression of HIV infection, and evaluating the effectiveness of an anti-HIV treatment administered to an animal, such as a human.Type: GrantFiled: October 28, 1992Date of Patent: October 31, 1995Assignee: The Government of the United States of America, as Represented by the Secretary, DHHSInventors: Larry O. Arthur, Louis E. Henderson
-
Patent number: 5441941Abstract: Certain new 1,2-dihydroellipticine compounds having activity against CNS specific cancer cell lines because of their ease of passage across the blood-brain barrier are disclosed along with formulations and methods for treating CNS cancers employing these compounds.Type: GrantFiled: December 21, 1993Date of Patent: August 15, 1995Assignees: The United States of America as represented by the Secretary of DHHS, Purdue Research FoundationInventors: Rudiger D. Haugwitz, Venkatachiala L. Narayanan, Mark Cushman, Jurjus Jurayj
-
Patent number: 5158940Abstract: Polysulfonated compounds such as suramin are used to treat immunoregulatory isorders. Particular use in the treatment of rheumatologic diseases such as rheumatoid arthritis is shown.Type: GrantFiled: February 14, 1990Date of Patent: October 27, 1992Assignee: The United States Government as represented by the Secretary, DHHSInventors: Renato V. LaRocca, Cy A. Stein, Michael R. Cooper, Charles E. Myers